

CONNECT

TaeWoong Medical Newsletter



Dear Valued Partners,

As the year comes to a close, we would like to express our sincere appreciation for your continued trust and partnership.

This year has been one of challenges, achievements, and meaningful growth — none of which would have been possible without your dedication and support.

We take great pride in working alongside you and look forward to achieving even greater growth together through continued collaboration.

In the coming year, we are excited to continue our journey of innovation and success together, and we wish you:

- New opportunities
- Prosperity
- Happiness


May you enjoy a joyful holiday season and a healthy, successful, and fulfilling New Year.

On behalf of the entire team at TaeWoong Medical

LOOKING BACK TAEWOONG MEDICAL'S 2025


International congresses are TaeWoong Medical's preferred platform for engaging with customers and partners on a global scale.

TaeWoong Medical's participation in five of the world's leading gastroenterology congresses this year reinforces its commitment to innovation and global leadership in the medical device industry.



ESGE

April 3-5
Barcelona, Spain




DDW

May 3-6
San Diego, USA



SPED

August 28-31
Lima, Peru



UEGW


October 4-7
Berlin, Germany



APDW

November 18-22
Suntec, Singapore





ESGE DAYS 2025

April 3-5 / Barcelona, Spain

TaeWoong Medical proudly participated in ESGE Days 2025, held from April 3rd to 5th in Barcelona, Spain.

Our booth was filled with energy and engagement as attendees explored our advanced EUSRA and HOT SPAXUS at our dedicated hands-on zone.

We sincerely appreciate everyone who visited and supported us throughout the Congress — it was a fantastic opportunity to connect with leading endoscopists and showcase our commitment to advancing interventional endoscopy.

DDW 2025

May 3-6 / San Diego, USA

TaeWoong Medical proudly participated in Digestive Disease Week (DDW) 2025, held from May 3–6 in San Diego, California.

Our booth featured five dedicated product stations — Endoscopy, Accessory, RFA, Stent – US, and Stent – Global — each designed to showcase our latest innovations and commitment to advancing gastrointestinal care. We appreciated the enthusiastic engagement and insightful discussions with attendees throughout the event.

Thank you to everyone who visited our booth and connected with our team—your support motivates us to continue pushing the boundaries of medical technology.





SPED 2025

August 28-31 / Lima, Peru

SPED 2025 – Panamerican Digestive Diseases Week Held in Lima, Peru from August 28 to 31, 2025, SPED 2025 brought together over 2,000 professionals from across the continent for an exceptional week of scientific exchange and collaboration.

We were honored to participate as an exhibitor and contribute to this landmark event in the field of gastroenterology.



UEGW 2025

October 4-7 / Berlin, Germany

At UEGW 2025 in Berlin (October 4–7), TaeWoong Medical was excited to welcome visitors to Booth 4.47, where we highlighted our growing presence in the global gastrointestinal device market.

We enjoyed reconnecting with the GI community, sharing our evolving product portfolio, and discussing our vision for continued global expansion. The event provided a great opportunity to meet clinicians, distributors, and industry partners, and to exchange valuable insights that support ongoing innovation in endoscopic and stent solutions.

Thank you to everyone who stopped by — your interest, feedback, and collaboration help us continue advancing care for patients worldwide.




APDW 2025

November 18-22 / Suntec, Singapore

At APD 2025 in Singapore (November 18–22), TaeWoong Medical was pleased to participate in one of the region's most influential gatherings in digestive health, held under the theme "Innovate, Integrate, Invigorate: a new era in Gastroenterology."

The event provided an excellent opportunity to connect with leading gastroenterologists, hepatologists, endoscopists, and GI-surgery specialists, showcasing our evolving device portfolio and sharing our vision for global expansion. Engaging with clinicians, distributors, and industry partners allowed for meaningful exchanges on emerging clinical needs and technology trends, providing valuable insights that guide the development of next-generation endoscopic and stent solutions.

We sincerely thank everyone who visited our booth — your interest, feedback, and collaboration reinforce TaeWoong Medical's commitment to advancing patient care worldwide through continuous innovation.



SPECIAL SECTION

EVENTS & GIVE AWAY

For more than three decades, TaeWoong Medical has continued to grow, nurtured by the trust, loyalty, and unwavering support of our valued customers.

Each time we participate in an international congress, it is the warm visits and encouragement from our esteemed guests that make every event truly meaningful.

With heartfelt gratitude, we prepared a small yet memorable event at DDW and UEGW to share joy and create lasting memories with our clients and partners.

Though simple in form—a charming capsule-draw machine—this experience brought delight and smiles to many visitors who left our booth carrying both fond memories and a thoughtful gift, a token of our appreciation.

We sincerely thank everyone who visited us, and we look forward to reuniting in 2026 with the same joy and spirit that have carried us this far.



New Publications

Endoscopic ultrasound-guided radiofrequency ablation for treatment of pancreatic neuroendocrine tumors : Multicenter prospective study

by Gianenrico Rizzatti et al.

[Endosc Int Open. 2025 Oct 16;13:a26895949.]



[LEARN MORE](#)

Background and study aims

Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has been proposed as a minimally invasive alternative to surgery for treatment of both functional (F-) and non-functional (NF-) pancreatic neuroendocrine tumors (PanNETs). We performed a large prospective multicenter study to evaluate safety and effectiveness of EUS-RFA in patients with F- and NF-PanNETs.

Patients and methods

Patients with F- (≤ 2 cm) and NF-PanNETs (15 mm-25 mm) were prospectively enrolled over a 43-month period. The primary aim was safety, defined as rate of adverse events (AEs). The secondary aim was effectiveness defined as complete disappearance of the hormonal secretion syndrome in F- PanNETs, whereas for NF-PanNETs, complete response was defined as absence of enhancing tissue and of detectable lesion at magnetic resonance imaging/computed tomography scan and Gallium-positron emission tomography, respectively. The EUSRA 19G needle was used in all patients. After treatment completion, follow-up was performed for 1 year.

Results

During the study period, a total of 60 patients were enrolled, 30 with insulinomas and 30 with NF-PanNETs (mean lesion size 14.5 ± 4.5 mm). In 78.3% of patients, a single RFA session was performed. Overall, AEs occurred in nine of 60 patients (15%), in four patients (13.3%) with insulinomas and in five (16.7%) with NF-PanNETs, with only one severe AE. Complete insulin hypersecretion symptom resolution was obtained in 29 of 30 patients (96.7%) with insulinomas, whereas for NF-PanNETs, complete radiological response was obtained in 22 of 25 patients (88%) with long-term follow up.

Conclusions

Our prospective international multicenter study demonstrated that EUS-RFA is highly safe and effective for the treatment for both F- and NF-PanNETs.



New Publications

Endoscopic ultrasound-guided hepatogastrostomy (EUS-HGS) as a rescue biliary drainage strategy : experience in a tertiary care hospital in Costa Rica

by Enrique Evans Rodríguez et al.

[Rev Gastroenterol Peru. 2025 Jul-Sep;45(3):250-254.]



[LEARN MORE](#)

Introduction

Endoscopic retrograde cholangiopancreatography (ERCP) is the standard treatment for biliary drainage, but it may fail in patients with advanced malignant obstruction. In such cases, endoscopic ultrasound-guided hepatogastrostomy (EUS-HGS) has emerged as an effective therapeutic alternative. This retrospective study describes the experience of Hospital San Juan de Dios, Costa Rica, with EUS-HGS as a rescue drainage strategy after failed ERCP.

Objective

To describe the institutional experience with EUS-HGS as a biliary drainage technique in patients with unresectable malignant obstruction and failed ERCP, evaluating its technical feasibility, clinical efficacy, and safety in a high-complexity public center.

Materials and Methods


Twenty consecutive patients treated with EUS-HGS between April 2023 and March 2024 were included. Clinical success was defined as a $\geq 50\%$ reduction in total bilirubin at 30 days. Adverse events, procedure time, and technical success were evaluated.

Results

Technical success was achieved in 100% of cases (20/20). Nineteen patients (95%) reached clinical success. The mean procedure time was 18 minutes. No major complications or mortality were reported. Three patients (15%) presented mild adverse events (abdominal pain and minimal bleeding).

Conclusions

EUS-HGS proved to be a safe, effective, and reproducible technique in patients with failed ERCP. The institutional experience supports its use in public centers with trained personnel, strengthening its role in the management of complex malignant biliary obstruction.



COMMUNICATION

(FEAT. SOCIAL MEDIA)

TaeWoong values online marketing as a powerful tool for real-time engagement with customers worldwide.

Over the past year, our LinkedIn followers have grown **by more than 20%**, with our conference updates being the most well-received.

We remain committed to sharing timely and diverse updates to strengthen our connection with customers.



We're excited to meet you at the Asian Pacific Digestive Week (APDW 2025) — one of the most significant gatherings for the digestive health community in Asia.

Visit TaeWoong Medical at Booth #42 to explore our latest GI stenting innovations and discover how we're advancing minimally invasive treatment technologies for better patient outcomes.

Let's connect, share insights, and shape the future of endoscopy together!




We had an amazing time connecting with so many visitors throughout the exhibition! Our booth was full of inspiring conversations, new ideas, and global collaborations.

And our small booth event — the Claw Machine — completely stole the show! It brought fun, energy, and smiles to everyone who stopped by

Thank you to everyone who visited TaeWoong Medical at UEGW 2025.

Your support and engagement made this congress truly special, and we look forward to seeing you again soon!






Workshops



Hands-on



**On-demand
contents**



Education at the Core of Safe and Effective Treatment



This year marks the 17th anniversary of the EUSRA training program launched in collaboration with Dr. Barthet and his team. To date, we have trained more than 100 physicians from around the world, providing participants with hands-on experience and the opportunity to acquire advanced knowledge.

TaeWoong Medical continues to support and host this workshop each year in pursuit of enhancing the expertise of medical professionals and improving the quality of life for patients worldwide. The specialists who have completed this training are now applying their skills across the globe to care for patients in need.

This year, the program was held twice—in May and October—during which participants had the privilege of learning from Professor Barthet's outstanding instruction and sharing in his extensive expertise.

Empowering Physicians Through Practice




For physicians, hands-on practice is paramount. We are dedicated to providing ample resources to help doctors refine their skills with our products.

This includes developing procedural training tools specifically designed for our devices and offering as many opportunities as possible for practice with the actual products.

Our commitment is to support medical professionals in delivering the highest standard of care through continuous learning and practice.

TaeWoong OTC: Your Comprehensive Resource Hub



TaeWoong OTC serves as a dynamic archive, regularly updated with the latest data on TaeWoong products.


Missed a symposium?


You can rewatch it anytime through OTC. Additionally, key publications and major papers are not only available on OTC but are also shared directly via email.

Our goal is to provide you with as much valuable information as possible, ensuring you stay informed and empowered.

► SPECIALTY ► Gastroenterology ► Biliary Stenting ► ARTICLE

ARTICLE


[PDF](#)


[ARTICLE](#)

KAFFES™_Intraductal fully covered self-expandable metal stent versus multiple...


[PDF](#)

[ARTICLE](#)

[PDF](#)

[ARTICLE](#)

[PDF](#)

[ARTICLE](#)

[PDF](#)

[ARTICLE](#)

[PDF](#)

[ARTICLE](#)

[PDF](#)

[ARTICLE](#)

[PDF](#)

[ARTICLE](#)


[PDF](#)


[ARTICLE](#)

GIORBOR™_Feasibility of EUS-guided hepaticogastrostomy for...

Original Article

Feasibility of EUS-guided hepaticogastrostomy for inoperable malignant hilar biliary strictures

Jérôme Winkler, Fabrice Cailliot, Jean-Philippe Ratner, Erwan Borlier, Christian Pesenti, Marc Giovannini
*Department of Endoscopy, Institut Paoli-Calmettes, Marseille, France

ABSTRACT

Background and Objectives: EUS-guided biliary drainage (EUS-BD) has emerged as a complementary technique for primary drainage or as a rescue technique after failed endoscopic retrograde cholangiography. The objective of this study was to demonstrate the feasibility of EUS-BD for malignant hilar strictures (MHS). Both as an initial and rescue procedure.

Patients and Methods: This study was a retrospective work based on a prospective registry of patients with malignant drainage (MD) of the biliary tract. For this analysis, only patients who underwent EUS-BD drainage were included. The drainage procedure could be performed by EUS-BD alone or in combination with another technique: for initial drainage or rescue drainage. Results: Between January 2013 and September 2018, 20 patients were included. The mean patient age was 68 years. Seven patients had primary liver tumors and 13 had obstructive caused by metastases. Two patients had Type II lesions, 7 had Type IIIA, 2 had Type IIB, and 7 had Type IV lesions. For initial drainage, 2 patients underwent EUS-BD alone and 18 underwent EUS-BD in combination with another technique: 1) combined with endoscopic retrograde cholangiography (ERC), 2) with percutaneous transhepatic drainage, and 3) with ERC and percutaneous transhepatic drainage. The technical success rate for EUS-BD in the drainage of MHS was 100%, and the clinical success rate was 95%. The mean percentage of liver drained was 84%, with an average 1.7 endoscopic sessions and an average 2.7 procedures. The early complication rate was 5% and the mortality rate was 5%. Five EUS-BD/ERC combination drainage procedures were performed in one session and six were performed in two sessions with similar complication rates and percentages of liver segments drained. Conclusion: EUS-BD is a feasible and safe technique for initial drainage and for rescue drainage. The EUS-BD/ERC combination seemed to be useful in cases of complex stricture and could be performed during the same session or in two sessions.

Key words: EUS-guided biliary drainage, feasibility, hilar malignant stricture

INTRODUCTION

Since being first described in 2001,⁽¹⁾ EUS-guided biliary drainage (EUS-BD) has demonstrated its feasibility, while ERCP fails and then in the drainage of resectable malignant hilar stricture (MHS).

In this case, biliary drainage is the main palliative therapeutic measure. Currently, the European Society of Gastrointestinal Endoscopy (ESGE) guidelines

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: info@taewoong_medical.com

How to cite this article: Winkler J, Cailliot F, Ratner JP, Borlier E, Pesenti C, Giovannini M. Feasibility of EUS-guided hepaticogastrostomy for inoperable malignant hilar biliary strictures. *Endosc. Intest. Dig.* 2020;10(4):4.

Address for correspondence:
 Dr. Jérôme Winkler, Department of Endoscopy, Institut Paoli-Calmettes, Marseille, France. E-mail: jerome.winkler@ipcm.fr
 Received: 2020-01-31; Accepted: 2020-09-28; Published online: 2021-01-05

© 2021 TAEWOONG MEDICAL PUBLISHING CO. LTD. | PUBLISHED BY TAEWOONG MEDICAL

Please click below the link for seeing the original article.

[More View](#)

PLANS FOR 2026

MARK YOUR CALENDAR

*The listed dates indicate the exhibition period.



CONFIRMED >

DDW

Chicago, USA

3-5, May

CONFIRMED >

ESGE Days

Milano, Italy

14-16, May

TBC >

EPC/IAP

Istanbul, Turkiye

24-27, June

CONFIRMED >

ENDO

Cape Town, South Africa

24-26, September

CONFIRMED >

UEG WEEK

Barcelona, Spain

18-20, October

CONFIRMED >

APDW

Manila, Philippines

26-28, November